文献速递头颈部肿瘤放疗

头颈癌术后放疗剂量-反应关系与病理风险分组的前瞻性随机试验最终报告

Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-07-10

这项3期随机试验评估头颈鳞癌术后放疗(PORT)剂量与病理风险分组的剂量-反应关系。264例患者按风险分组随机接受57.6/63 Gy或63/68.4 Gy(1.8 Gy/次),结果显示不同剂量水平间肿瘤控制无统计学显著差异;多因素分析中阳性切缘、包膜外侵犯(ECE)和治疗包时间(TPT)≥85天与更差结局独立相关。

要点

  • 低危组57.6 Gy与63 Gy、高危组63 Gy与68.4 Gy之间肿瘤控制无显著差异。
  • 阳性切缘、ECE和TPT≥85天是多因素分析中 worse 局控的独立相关因素。
  • 年龄≥57岁、阳性切缘、ECE和TPT≥85天与更差总生存独立相关。

核心结论

  • 术后放疗剂量从57.6 Gy增至68.4 Gy(1.8 Gy/次、未联合化疗)未显著改善头颈鳞癌肿瘤控制。
  • 多因素分析中唯一显著的治疗变量是治疗包时间(TPT)。
  • 阳性手术切缘和/或淋巴结包膜外侵犯仍是最显著的预测性病理因素。

研究设计与样本

  • 3期前瞻性随机试验,纳入接受原发手术且需PORT的AJCC III或IV期口腔、口咽、下咽或喉鳞癌患者。
  • 原发部位和受累颈部按累积评分独立分为较低危或较高危组。
  • 较低危组随机接受57.6或63 Gy,较高危组随机接受63或68.4 Gy,均1.8 Gy/次。
  • 共纳入264例患者。

主要发现

  • 5年实际局控率为67%。
  • 27%患者记录到第二原发癌。
  • 5年和10年无远处转移率分别为64%和60%。
  • 5年和10年总生存率分别为32%和20%。
  • 较低危组和较高危组内不同剂量水平间肿瘤控制均无统计学显著差异。

关键数值与推荐

  • 非白人种族(P=.0003)、阳性手术切缘(P=.009)、包膜外侵犯(P=.01)和TPT≥85天(P=.002)是更差局控的独立相关因素。
  • 年龄≥57岁(P<.0001)、阳性手术切缘(P=.01)、包膜外侵犯(P=.026)和TPT≥85天(P=.003)与更差总生存独立相关。

临床怎么用

  • 头颈鳞癌术后放疗在57.6至68.4 Gy范围内增加剂量未显著改善肿瘤控制。
  • 应关注并尽量缩短治疗包时间(TPT),其与局控和总生存独立相关。
  • 阳性手术切缘和/或淋巴结包膜外侵犯患者仍属高危,需作为重点预测因素考量。

局限性

  • 该最终报告未联合化疗,结论外推至同期放化疗人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To present the long-term and final report of a phase 3 trial designed to assess dose-response relationship for postoperative radiation therapy (PORT) and pathologic risk groups in head and neck cancer. METHODS AND MATERIALS: Patients who underwent primary surgery for American Joint Committee on Cancer stage III or IV squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx and who required PORT were eligible. Patients' primary sites and involved necks were independently assigned to higher- or lower-risk categories based on a cumulative point score representing increasing risk of recurrence. The sites in the lower-risk group were randomized to receive 57.6 or 63 Gy and those in the higher-risk group were randomized to receive 63 or 68.4 Gy, all at 1.8 Gy per fraction. RESULTS: A total of 264 patients were included. The actuarial 5-year locoregional control rate was 67%. A second primary cancer was documented in 27% of patients. The 5- and 10-year freedom-from-distant metastasis rates were 64% and 60%, respectively, whereas the 5- and 10-year overall survival rates were 32% and 20%, respectively. There was no statistically significant difference in tumor control between different dose levels in both the lower- and higher-risk groups. On multivariate analysis, nonwhite race (P=.0003), positive surgical margins (P=.009), extracapsular extension (ECE, P=.01), and treatment package time (TPT) ≥85 days (P=.002) were independent correlates of worse locoregional control, whereas age ≥57 years (P<.0001), positive surgical margins (P=.01), ECE (P=.026), and TPT ≥85 days (P=.003) were independently associated with worse overall survival. CONCLUSIONS: This long-term report of PORT delivered at 1.8 Gy/d to total doses of 57.6 to 68.4 Gy without chemotherapy for head and neck squamous cell carcinoma demonstrated that increasing dose did not significantly improve tumor control. On multivariate analysis, the only significant treatment variable was TPT. The results confirm that positive surgical margins and/or nodal ECE remains the most significant predictive pathologic factors.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Rosenthal DI, Mohamed ASR, Garden AS, et al. Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 28721881. doi:10.1016/j.ijrobp.2017.02.218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。